Read Pharmafocus January/February 2019 edition online now!
pharmafile | January 30, 2019 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | AI, Cancer, Counterfeit drugs, NHS, Pharmafocus, WHO, brexit, pharma, vaccines
We’re slowly edging towards warmer months, but the New Year brings more than just the promise of more amicable weather; in a manner reminiscent of past years, industry M&A is off to an explosive start, as multinational drug firm Bristol-Myers Squibb announced within the first days of the year that it had entered into an agreement to acquire Celgene for approximately $74 billion – the biggest pharma acquisition ever. You can read the full story on our front page.
Elsewhere, the World Health Organization has revealed an annual list of what it considers to be the greatest threats to global health, and there were a few surprises alongside expected dangers such as antimicrobial resistance, HIV and weak primary healthcare, including air pollution, climate change and vaccine hesitancy. You can find the full list on page 7.
In R&D, new research has promised to fight cancer in a way that almost borders on science fiction: by converting the tumour’s cells into fat. You can read about the project, as well as exclusive commentary from the paper’s lead author Dana Ishay Ronen, on page 8. You can find these stories and many more in our latest issue.
Also, be sure not to miss our full-length features exploring how artificial intelligence can address the industry’s drug development challenges, and why the counterfeit drugs problem is not what it seems.
Read the January/February edition of Pharmafocus online now!
Related Content
NICE recommends migraine treatment for NHS use
The National Institute for Health and Care Excellence (NICE) has shared draft guidance recommending AbbVie’s …
Geneos Therapeutics shares data from phase 1/2 trial for cancer vaccine
Geneos Therapeutics has announced that it has published positive safety, immunogenicity and efficacy data from …
Curve Therapeutics’ CSO publishes research on HIF inhibition for cancer treatment
Curve Therapeutics has announced that its chief scientific officer, Professor Ali Tavassoli has published research …
